EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial

Lev Demidov, Igor Samoylenko, Galina Kharkevich, Kristina Orlova, Vladimir Moiseenko, Igor Utyashev, Daniil Stroyakovskiy, Vadim Kozlov, Anastasia Zimina, Anastasia Mochalova, Svetlana Demidova, Marina Lyadova und 38 weitere

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115674 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Lev Demidov und 49 weiteren Autor:innen. Beteiligte Einrichtung: FSBI "N.N. Blokhin National Medical Research Center for Oncology", MoH, Moscow, Russian Federation. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Russian Venture Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsAntibodies, Monoclonal, HumanizedCTLA-4 AntigenHumansMaleFemaleMiddle AgedAgedDouble-Blind MethodAdultTreatment OutcomeProgression-Free SurvivalAged, 80 and over

Stichwörter der Autor:innen

Anti-CTLA-4Anti-PD-1NurulimabProlgolimabUnresectable and metastatic melanoma

Substanzen

Programmed Cell Death 1 ReceptorImmune Checkpoint InhibitorsAntibodies, Monoclonal, HumanizedPDCD1 protein, humanCTLA-4 AntigenCTLA4 protein, human

Autor:innen und Institutionen

  • FSBI "N.N. Blokhin National Medical Research Center for Oncology", MoH, Moscow, Russian Federation.
  • SBHI "N.P. Napalkov St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncology)", St. Petersburg, Russian Federation.
  • Hadassah Medical LCC, Moscow, Russian Federation.
  • Moscow City Oncology Hospital No. 62, Moscow, Russian Federation.
  • SBHI "Novosibirsk Regional Clinical Oncology Dispensary", Novosibirsk, Russian Federation.
  • BHI "Clinical Oncology Dispensary", Omsk, Russian Federation.

Förderung

  • Russian Venture Company

Zitieren

APA

Demidov, L., Samoylenko, I., Kharkevich, G., Orlova, K., Moiseenko, V., Utyashev, I., Stroyakovskiy, D., Kozlov, V., Zimina, A., Mochalova, A., Demidova, S., Lyadova, M., Kutkovich, A., Skopin, P., Kovalenko, N., Safina, S., Volkov, V., Semiletova, Y., Vaschenko, V., …, & Kryukov, F. (2025). Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115674

Vancouver

Demidov L, Samoylenko I, Kharkevich G, Orlova K, Moiseenko V, Utyashev I, et al. Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115674

BibTeX
@article{Demidov2025,
  author = {Demidov, Lev and Samoylenko, Igor and Kharkevich, Galina and Orlova, Kristina and Moiseenko, Vladimir and Utyashev, Igor and Stroyakovskiy, Daniil and Kozlov, Vadim and Zimina, Anastasia and Mochalova, Anastasia and Demidova, Svetlana and Lyadova, Marina and Kutkovich, Andrey and Skopin, Pavel and Kovalenko, Nadezhda and Safina, Sufia and Volkov, Vitaliy and Semiletova, Yulia and Vaschenko, Vera and Kislov, Nikolay and Poltoratskiy, Artem and Shumskaya, Irina and Kolomiets, Sergey and Sobolev, Alexandr and Belogortsev, Igor and Odintsova, Svetlana and Rastogi, Sameer and Andabekov, Timur and Penkov, Konstantin and Semenova, Anna and Obukhov, Alexey and Belyakovsky, Vasiliy and Yurchenkov, Alexander and Gladkov, Oleg and Neve, Rakesh and Falaleeva, Natalia and Poddubskaya, Elena and Vaibhav, Amale and Kirtbaya, Dmitriy and Chapko, Yana and Smagina, Maria and Fadeeva, Natalya and Sorokina, Irina and Mikhailova, Evgenia and Linkova, Yulia and Zinkina-Orikhan, Arina and Lutskii, Anton and Gabidullin, Rishat and Rzaev, Roman and Kryukov, Fedor},
  title = {Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115674}
}
Kostenlos starten →